IL-10 is expressed in patients with breast cancer and has been associated with poor prognosis.35,50 A recent preclinical study combining PEGylated human IL-10 (AM0010 or pegilodecakin) with docetaxel in 4T1 (TNBC) mouse models demonstrated synergy, with complete responses in 75% of mice.51 However, given its paradoxical role in tumor development and uncertainty about how best to shift activities to tumor inhibition (rather than tumor promotion), few IL-10 targeting agents are in clinical development. This evidence concerns the gene IL10 and breast carcinoma.